Trial Profile
A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms ACCORDO
- Sponsors Lundbeck A/S
- 02 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2012 Interim tolerability results reported at the 16th International Congress of Parkinson's Disease and Movement Disorders
- 22 Mar 2012 Planned End Date changed from 1 Feb 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.